A straightforward approach for converting existing batch production to an integrated continuous manufacturing suite by adopting membrane‐based technology
Biotechnology Progress · 2026
DOI: 10.1002/btpr.88523 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Progress, 2026. Verfasst von Mingyue Fang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Non-GMP Pilot Production, WuXi Biologics, Shanghai, China. Hauptthemen laut MEDLINE: Membranes, Artificial, Bioreactors, Antibodies, Monoclonal, Batch Cell Culture Techniques. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
The rapidly developing antibody market poses challenges to the production cost and efficiency, which can be addressed through continuous process. However, a hurdle of high capital investment remains a concern especially for the company with existing fed‐batch capacity. This study proposes a straightforward approach to convert existing batch production suites into continuous ones using membrane‐based technology. A conceptual validation was conducted at a 100 L pilot scale, and a head‐to‐head comparison was carried out. The results demonstrated that Protein A membrane chromatography could achieve a productivity 6.3 times higher than that of periodic counter‐current chromatography (PCC), without requiring the purchase of any dedicated equipment. Using Q membrane, compared with traditional column anion exchange chromatography, can achieve a 16‐fold increase in load capacity and a 25‐fold increase in productivity. Finally, VF‐UF/DF (Virus Filtration‐Ultrafiltration/diafiltration) linkage process was designed, resulting in a 20% reduction in process time. During the 23‐day upstream perfusion and 15‐day downstream processing, the cumulative titer reached 51.0 g/L, with an 83.1% yield in downstream processing. With downstream process time shortening from 4 to 1.5 days, the process capacity could be improved by 8 times using the existing batch production suites and the same facility area. PATs, including ultra‐performance liquid chromatography, Raman spectroscopy, FlowVPX, and an inline turbidity meter, were integrated to monitor process CQAs (Critical Quality Attributes): monomer purity, protein concentration, and turbidity, to enable efficient process control in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Non-GMP Pilot Production, WuXi Biologics, Shanghai, China.
- Bioprocess Research and Development, WuXi Biologics, Shanghai, China.
- Biologics Development Business Unit, WuXi Biologics, Shanghai, China.
Zitieren
APA
Fang, M., Shi, C., Zhou, A., Zhu, H., Zhou, H., Gu, S., & Zhou, W. (2026). A straightforward approach for converting existing batch production to an integrated continuous manufacturing suite by adopting membrane‐based technology. Biotechnology Progress. https://doi.org/10.1002/btpr.88523
Vancouver
Fang M, Shi C, Zhou A, Zhu H, Zhou H, Gu S, et al. A straightforward approach for converting existing batch production to an integrated continuous manufacturing suite by adopting membrane‐based technology. Biotechnology Progress. 2026. doi:10.1002/btpr.88523
BibTeX
@article{Fang2026,
author = {Fang, Mingyue and Shi, Ce and Zhou, Anmin and Zhu, Huilin and Zhou, Hang and Gu, Sherry and Zhou, Weichang},
title = {A straightforward approach for converting existing batch production to an integrated continuous manufacturing suite by adopting membrane‐based technology},
journal = {Biotechnology Progress},
year = {2026},
doi = {10.1002/btpr.88523}
}
EUVIMED